Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
10 November 2004Website:
http://www.abvcpharma.comNext earnings report:
15 November 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Mon, 28 Oct 2024 23:56:43 GMTDividend
Analysts recommendations
Institutional Ownership
ABVC Latest News
FREMONT, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) -- ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company focused on innovative treatments in ophthalmology, CNS (central nervous system), and oncology/hematology, today announced the receipt of an additional $50,000 in licensing fees from AiBtl BioPharma Inc. With this payment, ABVC has received a total of $346,000 in licensing fees from its strategic partners, supporting our partner's belief in our mission. ABVC has received 23M AiBtl shares as part of the first milestone of the licensing fees and will obtain royalties up to $100M after the product launches.
• Executed Global Licensing Agreements that could provide up to $292 million in income • Received Cash Milestone Incomes of $116,000 • Achieved Significant Improvements in Earnings • Obtained Multiple Patents and FDA Approvals FREMONT, CA, Aug. 15, 2024 (GLOBE NEWSWIRE) -- ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, is pleased to announce its financial results and key operational highlights for the second quarter ended June 30, 2024. Key Financial and Operational Highlights: 1.
If you're wondering what is going on in the stock market today or which penny stocks to buy now that major indexes are lower, you're not alone. Earnings season mixed with economic data has resulted in a sharp downturn for the market.
What type of business is ABVC BioPharma?
ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation.
What sector is ABVC BioPharma in?
ABVC BioPharma is in the Healthcare sector
What industry is ABVC BioPharma in?
ABVC BioPharma is in the Biotechnology industry
What country is ABVC BioPharma from?
ABVC BioPharma is headquartered in United States
When did ABVC BioPharma go public?
ABVC BioPharma initial public offering (IPO) was on 10 November 2004
What is ABVC BioPharma website?
https://www.abvcpharma.com
Is ABVC BioPharma in the S&P 500?
No, ABVC BioPharma is not included in the S&P 500 index
Is ABVC BioPharma in the NASDAQ 100?
No, ABVC BioPharma is not included in the NASDAQ 100 index
Is ABVC BioPharma in the Dow Jones?
No, ABVC BioPharma is not included in the Dow Jones index
When was ABVC BioPharma the previous earnings report?
No data
When does ABVC BioPharma earnings report?
The next expected earnings date for ABVC BioPharma is 15 November 2024